LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Aandelen Lijst・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

70 -1.21

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

67.06

Max

71.47

Belangrijke statistieken
By Trading Economics
Inkomsten	292M 150M
Verkoop	-75M 377M
K/W Sectorgemiddelde	25.941 51.415
Winstmarge	39.832
Werknemers	423
EBITDA	-97M 185M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+19.1% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	218M 7.9B
Vorige openingsprijs	71.21
Vorige sluitingsprijs	70

Nieuwssentiment

By Acuity

50%

162 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

60.49 / 70.14 Steun & Weerstand

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 mei 2026, 22:54 UTC

Winsten

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mei 2026, 23:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 mei 2026, 23:51 UTC

Marktinformatie

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mei 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mei 2026, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 mei 2026, 23:17 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mei 2026, 23:16 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mei 2026, 23:15 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mei 2026, 23:14 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mei 2026, 23:02 UTC

Marktinformatie

Winsten

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mei 2026, 22:59 UTC

Marktinformatie

Winsten

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mei 2026, 22:24 UTC

Winsten

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mei 2026, 22:23 UTC

Winsten

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mei 2026, 22:23 UTC

Winsten

Xero FY International Revenue Growth 47%>XRO.AU

13 mei 2026, 22:22 UTC

Winsten

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mei 2026, 22:19 UTC

Winsten

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mei 2026, 22:19 UTC

Winsten

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mei 2026, 22:18 UTC

Winsten

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mei 2026, 22:16 UTC

Winsten

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mei 2026, 22:15 UTC

Winsten

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mei 2026, 22:15 UTC

Winsten

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mei 2026, 22:13 UTC

Winsten

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mei 2026, 22:12 UTC

Winsten

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mei 2026, 22:11 UTC

Winsten

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mei 2026, 22:11 UTC

Winsten

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mei 2026, 22:10 UTC

Winsten

Xero Did Not Declare a Dividend>XRO.AU

13 mei 2026, 22:10 UTC

Winsten

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mei 2026, 22:09 UTC

Winsten

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mei 2026, 22:00 UTC

Winsten

Cisco to Shed Jobs for All-In AI Push -- Update

13 mei 2026, 21:11 UTC

Winsten

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

19.1% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 84.48 USD 19.1%

Hoogste 96 USD

Laagste 66.41 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Halozyme Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

60.49 / 70.14Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

162 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.